Thanks for this. I was a bit perplexed at first glance at the data. I made a short note of it in a reply in someone's note. Thanks for fleshing it out more. The one thing that struck me was the age ranging from 18-87 with just 5% over 65 and a median of 42. Symptoms alleviation in 12 vs 13 days means that we are talking about the second of the bi-phasic, the cytokine inflammatory, phase. Not the viral replication phase. Imagine my naive thinking that reducing hospitalization, ICU and death was the goal.
Excellent points all around. And, yes the age range was very large and before making the claim that it was not beneficial for those who are not 'high risk', analysis by age group would have also been very helpful.
Sadly, I believe that Paxlovid was under utilized this past winter season in looking at the death data. I hope this doesn't deter more doctors since they were concerned about "rebound". Hopefully we will get new antivirals this year. I've been following/writing about a couple of promising candidates.
My immunologist , (I have PID) did not recommend paxlovid - in fact the academic medical center he is part of, does not use paxlovid . Perplexed , but trusting my docs. Thanks for explaining the science behind paxlovid!
Thanks for this. I was a bit perplexed at first glance at the data. I made a short note of it in a reply in someone's note. Thanks for fleshing it out more. The one thing that struck me was the age ranging from 18-87 with just 5% over 65 and a median of 42. Symptoms alleviation in 12 vs 13 days means that we are talking about the second of the bi-phasic, the cytokine inflammatory, phase. Not the viral replication phase. Imagine my naive thinking that reducing hospitalization, ICU and death was the goal.
Excellent points all around. And, yes the age range was very large and before making the claim that it was not beneficial for those who are not 'high risk', analysis by age group would have also been very helpful.
Sadly, I believe that Paxlovid was under utilized this past winter season in looking at the death data. I hope this doesn't deter more doctors since they were concerned about "rebound". Hopefully we will get new antivirals this year. I've been following/writing about a couple of promising candidates.
My immunologist , (I have PID) did not recommend paxlovid - in fact the academic medical center he is part of, does not use paxlovid . Perplexed , but trusting my docs. Thanks for explaining the science behind paxlovid!